Mastopon-Treat (Progesterone)

Progesterone in Mastopon-Treat acts on the reproductive hormone pathway and is employed in several clinical settings.

• Luteal phase support in assisted reproduction: Enhances endometrial receptivity and supports early pregnancy.
• Prevention of preterm birth: Reduces risk of early delivery in at‑risk pregnancies.
• Hormone replacement therapy: Provides progestogenic activity to balance estrogen in menopausal women.

• Progesterone binds to intracellular progesterone receptors, forming a hormone‑receptor complex that interacts with DNA to regulate gene transcription. This modulation prepares and maintains the endometrium, supports implantation, and sustains early pregnancy, while also providing progestogenic activity that counteracts estrogen‑induced endometrial proliferation in hormone replacement therapy.

Progesterone administered vaginally may be associated with a range of adverse reactions.

Common Side Effects

• Vaginal irritation or burning
• Increased vaginal discharge
• Spotting or light bleeding
• Abdominal cramps or pelvic discomfort
• Breast tenderness
• Headache

Serious or Rare Side Effects

• Thromboembolic events (deep vein thrombosis, pulmonary embolism)
• Severe allergic reaction (rash, swelling, anaphylaxis)
• Significant vaginal bleeding
• Hepatic dysfunction (elevated liver enzymes)
• Adrenal suppression in prolonged high‑dose use

Use of Mastopon-Treat requires careful clinical assessment and monitoring.

• Contraindications: Do not use in patients with known hypersensitivity to progesterone or any excipients.
• Thromboembolic risk: Evaluate history of clotting disorders before initiating therapy.
• Liver function: Monitor hepatic enzymes in patients with pre‑existing liver disease.
• Dose minimisation: Employ the lowest effective dose for the shortest duration necessary.
• Patient education: Instruct patients to report signs of allergic reaction or abnormal bleeding promptly.
• Store at room temperature: Keep in the original packaging, protect from moisture and direct sunlight.

Progesterone can interact with several medication classes, influencing efficacy or safety.

Major Interactions (Avoid)

• Combined estrogen therapy without progesterone: Increases risk of endometrial hyperplasia.
• Anticoagulants (warfarin, direct oral anticoagulants): May enhance bleeding tendency.
• Strong CYP3A4 inducers (rifampicin, carbamazepine): Can markedly reduce progesterone levels.

Moderate Interactions (Monitor Closely)

• Antifungal agents (ketoconazole, itraconazole): May increase progesterone concentrations.
• Anticonvulsants (phenytoin, phenobarbital): May lower progesterone exposure.
• Herbal supplements (St. John’s wort): Potentially decreases progesterone effectiveness.